Sources inside of the White House tell The Chronicle that President Donald J. Trump is planning a major campaign pledge to commit more than $1 billion to cure the herpes virus before the end of his second term.
“In the last six months, we’ve built up a massive amount of private sector infrastructure around vaccine research and manufacturing,” the political staffer explains. “We are going to address COVID-19, and then we will have a massive over-capacity when it comes to vaccine research.”
“President Trump wants to leverage this excess research capacity to yield a vaccine for herpes and a slew of other chronic viral infections,” he says. “He will be pledging more than $1 billion in matching grants to fund large scale clinical trials of various pharmaceutical treatments and combinations of treatments of the virus.”
According to the World Health Organization, 3.7 billion people under age 50 have herpes simplex virus type 1 (HSV-1) — that’s 67% of the global population in that age bracket. Another 417 million people (11%) between ages 15 and 49 worldwide have herpes simplex virus type 2 (HSV-2).
Trump’s critics see the move as a cynical ploy to court the support of voters in the African American and LGBT communities, two populations with a considerably higher prevalence of the herpes infection.
“The problem with herpes research isn’t a lack of research avenues. The problem has been that Big Pharma makes a lot more money on a treatment than they ever could on cure. They would rather sell you a monthly treatment than a one-time cure,” the White House advisor explains.
“President Trump wants to correct that market failure,” he adds.
Herpes is contracted through direct contact with an active lesion or body fluid of an infected person, and is typically contracted through direct skin-to-skin contact.
On an annual basis, without the use of antivirals or condoms, the transmission risk of HSV-2 from infected male to female is about 8–11%. This is believed to be due to the increased exposure of mucosal tissue to potential infection sites. Transmission risk from infected female to male is around 4–5% annually. Suppressive antiviral therapy reduces these risks by 50%.
Antivirals also help prevent the development of symptomatic HSV in infection scenarios, meaning the infected partner will be seropositive but symptom-free by about 50%. Condom use also reduces the transmission risk significantly. As with almost all sexually transmitted infections, women are more susceptible to acquiring genital HSV-2 than men.
Asymptomatic carriers of the HSV-2 virus are still contagious.
I hope people see trump is helping their children cus children catch herpes 1 in elementary school just eating lunch or doing class work cus they put hands in mouths and it’s a virus related to causing a lot of other conditions people don’t realize it affects the brain and nervous system and it’s unfair to disregard this . We need to protect innocent children .
Am really grateful and thankful for what Dr kabaka has done for me with his herbs. I have be suffering from Genital herpes for good 5 years with no solution, the disease almost took my life and because I was unable to work and I was also loosing lots of money for medication, but one faithful day when I went online, I met lots of testimonies about this great man so I decided to give it a try and to God be the glory he did it. If you need his help or you also want to get cured just the way I got mine, He has cure for other deadly diseases like Herpes, Hiv/Aids, STD, Hepatitis, Cancer, you can also visit his website for further information http://www.drkabakasolutionhome.com